Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q6PJT7

UPID:
ZC3HE_HUMAN

ALTERNATIVE NAMES:
Mammalian suppressor of tau pathology-2; Renal carcinoma antigen NY-REN-37

ALTERNATIVE UPACC:
Q6PJT7; A8MY46; B4DXU8; B4DZW7; B4E2H4; G3V5R4; Q6MZU4; Q6PJ32; Q6PUI6; Q6PUI8; Q86TQ5; Q86TW0; Q86TW1; Q8NCT6; Q8NCZ3; Q8TDE2; Q9HAC9; Q9Y5A0

BACKGROUND:
The Zinc finger CCCH domain-containing protein 14, with alternative names Mammalian suppressor of tau pathology-2 and Renal carcinoma antigen NY-REN-37, is pivotal in regulating poly(A) tail length in neuronal cells, a process essential for RNA stability and translation. This protein's binding affinity for polyadenosine RNA oligonucleotides signifies its critical role in neuronal function and development.

THERAPEUTIC SIGNIFICANCE:
Given its association with Intellectual developmental disorder, autosomal recessive 56, Zinc finger CCCH domain-containing protein 14 represents a promising avenue for research into genetic therapies. The exploration of its functions and mechanisms could lead to breakthroughs in treatment options for intellectual developmental disorders, emphasizing the importance of continued research in this area.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.